MODEL VERDICT
Century Therapeutics, Inc. (IPSC)
Relative Valuation•Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Popular:
Composite score derived from valuation, quality, and risk factors
Quantitative model thresholds · For educational and research purposes only
| Methodology | Fair Value | vs Current | Weight | Quality | Status |
|---|---|---|---|---|---|
| EV To Revenue 182 industry peers | $13.04 | +568.7% | 4% | B | Data |
| Price / Sales 184 industry peers | $12.19 | +525.1% | 3% | B | Model Driven |
| Weighted Output Blended model output | $25.62 | +1214.0% | 100% | 48 | SIGNIFICANTLY UNDERVALUED |
Cross-sectional regression predicting expected multiples based on growth, margins, ROIC, and beta.
| Multiple | Avg | Median | Min | Max | Std |
|---|---|---|---|---|---|
| P/TBV | 1.22 | 1.02 | 0.62 | 2.20 | 0.68 |
| P/B Ratio | 1.18 | 1.02 | 0.49 | 2.20 | 0.72 |
| P/S Ratio | 52.38 | 56.99 | 12.06 | 88.11 | 38.24 |
Based on our peer multiples analysis with 5 valuation metrics, the model estimates IPSC's fair value at $25.62 vs the current price of $1.95, implying +1214.0% upside potential. Model verdict: Significantly Undervalued. Confidence: 48/100. This is a quantitative estimate, not a recommendation.
The blended fair value of $25.62 is calculated using four lenses: industry median multiples (40%), historical multiples (30%), forward estimates (20%), and quality-adjusted multiples (10%). Monte Carlo simulation (10,000 iterations) gives a range of $11.32 (P10) to $39.57 (P90), with a median of $24.80.
IPSC's current P/E of -1.2x compares to the industry median of 23.5x (45 peers in the group). This represents a -105.2% discount to the industry. The historical average P/E is N/Ax over 0 years. Signal: Deep Discount.
9 analysts cover IPSC with a consensus rating of Buy. The consensus price target is $4.00 (range: $4.00 — $4.00), implying +105.1% upside from the current price. Grade breakdown: Strong Buy (0), Buy (7), Hold (2), Sell (0), Strong Sell (0).
The model confidence score is 48/100, based on: data completeness (6), peer quality (25), historical depth (10), earnings stability (5), and model agreement (2). Cyclicality penalty: -0 points. The model shows moderate agreement across inputs.
The model flags several key risks: (1) Macro/regulatory risks are not captured in this model but remain material.
Peak earnings risk data is not available for IPSC.
No. This dashboard is a quantitative research tool for educational and informational purposes only. It is not investment advice, a solicitation, or a recommendation to buy, sell, or hold any security. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, signals, and scenarios are the result of automated quantitative computations and should not be construed as professional financial guidance. You should consult a qualified, licensed financial advisor before making any investment decisions. Past model performance is not indicative of future results.